Other related rapalogues, such as Everolimus, Temsirolimus, and Ridaforolimus, targeting PI3K/AKT/mTORC1 axis have been tested in clinical trials, and successful clinical trials have resulted in FDA approval for Everolimus and Temsirolimus in the treatment of renal cell carcinoma and selected breast cancers. This evidence concerns the gene PIK3CA and breast cancer.